

In Advanced Prostate Cancer... Bone Metastasis Is a Killer¹




THERE ARE MULTIPLE SYMPTOMS ASSOCIATED WITH BONE METASTASIS

- Fatigue is the most stressful symptom of which patients with mCRPC complain²
- 68% of patients underreport their symptoms^a
- A complete review/discussion of patient history is critical to reveal symptoms associated with bone metastatic disease in advanced prostate cancer

Symptomatic Bone Metastases	
Fatigue, generalized weakness ³	Impaired mobility ³
Anemia, neutropenia, thrombocytopenia ³	Mild sensory loss, numbness ³
Interference with daily activities ⁴	Loss of bladder and bowel function ³
Weakness in extremities ³	Neurologic impairment ⁵
Interference with sleep ⁴	Pain and discomfort ^{3,4}
Dyspnea ³	Loss of appetite ⁶

BONE METASTASIS IS CORRELATED WITH SIGNIFICANT MORTALITY¹

Bone Metastasis Leads to Poor Survival



Of the 23,087 patients with initial diagnosis of prostate cancer, 22,404 had no bone metastases and 569 presented with bone metastases.

In Advanced Prostate Cancer... Bone Metastasis Is a Killer¹




PROGRESSION FROM BONE METASTASIS TO MULTIPLE METASTATIC SITES DECREASES SURVIVAL IN CRPC⁷

- Mortality increases as the disease migrates from lymph nodes to bone to visceral tissue


Overall Survival for Multiple Sites of Metastases

Median Survival (95% CI)			
Lymph Nodes	Bone	Visceral	Bone plus Visceral
43 (35.1-50.9)	24 (22.9-25.1)	16 (12.9-19.1)	14 (12.0-15.9)



Reproduced from *Eur Urol*. Vol. 68, Issue 2. Gandaglia G et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Pages 325-334. Copyright 2015, with permission from Elsevier.

CHANGE YOUR CLINICAL APPROACH AS PROSTATE CANCER PROGRESSES



When cancer spreads to the bone, focus on bone metastatic disease⁹

CI, confidence interval; mCRPC, metastatic castration-resistant prostate cancer.

^aBayer. MenWhoSpeakUp website. Prostate Cancer Symptoms Survey: US Results, 2015.

References:

1. Nørgaard M et al. *J Urol*. 2010;184(1):162-167.
2. Colloca G et al. *Clin Genitourin Cancer*. 2016;14(1):5-11.
3. Farrell C. *Br J Nurs*. 2013;22(10):S4-S11.
4. Autio KA et al. *J Oncol Pract*. 2013;9(5):223-229.
5. Selvaggi G et al. *Crit Rev Oncol Hematol*. 2005;56(3):365-378.
6. Hamilton W et al. *Br J Gen Pract*. 2015;65(637):e516-522.
7. Gandaglia G et al. *Eur Urol*. 2015;68(2):325-334.
8. Halabi S et al. Published online March 7, 2016. *J Clin Oncol*. doi:10.1200/JCO.2015.65.7270.
9. Body JJ et al. *Nat Rev Urol*. 2015;12(6):340-356.